Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07215403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prescriptive Infusion Algorithm (PIA)

Study acronym: PIA
StatusNot Yet Recruiting
PhasePhase 2
SponsorAskBio Inc
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Dec 30, 2027 → Apr 30, 2028
See other at-risk trials from AskBio Inc

Record History

  1. Start date: Jul 15, 2026 to Nov 2026 Primary completion pushed from Dec 30, 2027 to Apr 30, 2028 · Trial sites expanded: 1 → 4 locations · Completion pushed from Mar 1, 2028 to Nov 1, 2028v3 Show 3 more changesShow less
    • Primary completion pushed from Dec 30, 2027 to Apr 30, 2028
    • Trial sites expanded: 1 → 4 locations
    • Completion pushed from Mar 1, 2028 to Nov 1, 2028
  2. Enrollment target: 12 to 18 Start date: May 1, 2026 to Jul 15, 2026 · Study description expanded, about 10 wordsv2 Show 2 more changesShow less
    • Start date: May 1, 2026 to Jul 15, 2026
    • Study description expanded, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AskBio Inc
9 trials monitored
See 3 trials at risk
Parkinson's Disease
1,435 trials monitored
See 62 trials at risk
This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery
Trial Details
NCT Number NCT07215403
Lead Sponsor AskBio Inc
Collaborators: Bayer
Conditions PARKINSON DISEASE (Disorder)
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov